Prophylactic vasopressin to reduce intraoperative blood loss and associated morbidities during myomectomy: A systematic review and meta-analysis of 11 controlled trials - 27/11/22
, Mohammed Ziad Jamjoom d, Abdullah AMA Almubarki e, Saud Owaimer Alsehaimi b, Safa Alabdrabalamir f, Saeed Baradwan g, Mohammed Abuzaid h, Majed Saeed Alshahrani i, Khalid Khadawardi j, Ehab Badghish k, Hanadi Bakhsh l, Maha Al Baalharith m, Ibtihal Abdulaziz Bukhari l, Afnan Baradwan n, Hany Salem a, b, Ismail A. Al-Badawi a, b, ⁎Abstract |
Objective |
To collate evidence from randomized controlled trials (RCTs) and nonrandomized controlled trials (NCTs) on the efficacy and safety of vasopressin versus passive control (placebo/no treatment) during myomectomy.
Methods |
Six information sources were screened until 25-June-2022. The Cochrane Collaboration tool and Newcastle–Ottawa Scale were used to evaluate the risk of bias. Data were summarized as mean difference or risk ratio with 95% confidence interval in a random-effects model.
Results |
Eleven studies, comprising 1067 patients (vasopressin=567 and control=500) were analyzed. For RCTs (n = 8), the overall quality included ‘high risk’ (n = 4), ‘low risk’ (n = 2), and ‘some concerns’ (n = 2). For NCTs (n = 3), the overall quality included ‘good’ (n = 2) and ‘fair’ (n = 1). The mean intraoperative blood loss, mean difference in hemoglobin level, mean difference in hematocrit level, rate of perioperative blood transfusion, and mean operative time were significantly reduced in favor of the vasopressin group compared with the control group. However, there was no significant difference between both groups regarding the mean hospital stay. Pertaining to safety endpoints, after omission of an outlier study, the rate of drug-related cardiovascular adverse events did not significantly differ between both groups. There was no quantitative evidence of publication bias for the endpoint of intraoperative blood loss.
Conclusion |
Among patients undergoing myomectomy, prophylactic administration of vasopressin was largely safe and correlated with significant reductions in intraoperative blood loss and associated morbidities compared with a passive control intervention. Nonetheless, the conclusions should be cautiously interpreted owing to the low-evidence quality and the used doses varied greatly between studies.
Le texte complet de cet article est disponible en PDF.Keywords : Leiomyoma, Vasopressin, Myomectomy, Blood, Bleeding, Meta-analysis
Plan
Vol 51 - N° 10
Article 102485- décembre 2022 Retour au numéro
Article précédent
- The effect of the delivery mode on the evolution of cervical intraepithelial lesions during pregnancy. A meta-analysis
- Athanasios Douligeris, Vasilios Pergialiotis, Kalliopi Pappa, Anastasia Mortaki, Savia Pittokopitou, Ioannis Rodolakis, Angeliki Papapanagiotou, Alexandros Rodolakis, George Daskalakis
- End-to-end versus side-to-end anastomosis after bowel resection for deep infiltrating endometriosis: A retrospective study
- Giovanni Pontrelli, Cristiano Huscher, Marco Scioscia, Federica Brusca, Umberto Tedeschi, Pantaleo Greco, Matteo Mancarella, Nicoletta Biglia, Lorenzo Novara
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?